Whole-Body Positron Emission Tomography—CT: Optimized CT Using Oral and IV Contrast Materials

“…Previous studies have shown that scaling errors, although small (mean maximum standardised surface uptake value difference 5-7%), can occur in areas with high iodine concentration (e.g. liver, spleen and aorta) on CT acquisition [19]. As a result of the CT-based attenuation correction when scaling algorithms are used, the resulting overestimation may occur and may lead to image artefacts in the emission data.…”

Section: High-density Attenuation Artefactsmentioning

confidence: 99%

Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration

Wever

Stroobants²,

Coolen³

et al. 2008

Eur Respir J

107

View full text Add to dashboard Cite

Lung cancer is a common disease and is a leading cause of death in many countries. The management of lung cancer is directed by an optimal staging of the tumour. Integrated positron emission tomography (PET)/computed tomography (CT) is an anatomo-metabolic imaging modality that has recently been introduced to clinical practice and combines two different techniques: CT, which provides very detailed anatomic information; and PET, which provides metabolic information. One of the advantages of PET/CT is the improved image interpretation. This improvement can result in the detection of lesions initially not seen on CT or PET, a more precise location of lesions, a better characterisation of the lesion as benign or malignant and a better differentiation between tumour and surrounding structures. Initial studies demonstrate better results for PET/CT in the staging of lung cancer in comparison with PET alone, CT alone or visual correlation of PET and CT. The purpose of the present article is to discuss technical aspects of integrated PET/CT and to attempt to outline how to introduce integrated PET/ CT in clinical and daily practice.

show abstract

“…contrast agents have advantages in improving the delineation of anatomic structures, the sensitivity in detecting pathologic lesions, and accuracy in lesion characterization, their routine use is controversial because of potential artifacts during CT-based attenuation correction. Highly concentrated focal radiodense contrast may result in an overestimation of FDG uptake in combined PET/CT [10][11][12][13][14][15]. However, when CT images of combined PET/CT are used for diagnostic purposes, those without i.v.…”

mentioning

confidence: 99%

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer

Sheen

et al. 2007

Ann Nucl Med

View full text Add to dashboard Cite

6.11% for aorta, 5.85% ± 4.99% for liver, 5.47% ± 6.81% for muscle, and 2.81% ± 3.05% for bone marrow, and those of SUV ave were 10.17% ± 9.00%, 10.51% ± 7.89%, 4.95% ± 3.89%, 5.66% ± 9.12%, and 2.49% ± 2.50%, respectively. The mean differences of SUV max between enhanced and nonenhanced PET/CT were 5.89% ± 3.92% for lung lesions (n = 41), 6.27% ± 3.79% for LNs (n = 76), and 3.55% ± 3.38% for metastatic lesions (n = 35), and those of SUV ave were 3.22% ± 3.01%, 2.86% ± 1.71%, and 2.33% ± 3.95%, respectively. Although one LN status changed from benign to malignant because of contrast-related artifact, there was no up-or downstaging in any of the patients after contrast enhancement. Conclusions An i.v. contrast agent may be used in PET/CT without producing any clinically signifi cant artifact.

show abstract

Whole-Body Positron Emission Tomography—CT: Optimized CT Using Oral and IV Contrast Materials

Abstract: Our whole-body PET-CT protocol provided good vascular and intestinal enhancement without compromising PET quality, leading to a potential improvement in the diagnostic capacity of the combined PET-CT examination.

Cited by 103 publications

References 6 publications

Low Kilovoltage CT of the Neck with 70 kVp: Comparison with a Standard Protocol

Low Kilovoltage CT of the Neck with 70 kVp: Comparison with a Standard Protocol

Integrated PET/CT in the staging of nonsmall cell lung cancer: technical aspects and clinical integration

Nonionic intravenous contrast agent does not cause clinically significant artifacts to 18F-FDG PET/CT in patients with lung cancer

Contact Info

Product

Resources

About